Affinity Capture Elution Coupled with Cell-based Cyclic Adenosine Monophosphate Assay as a Platform Method for Detection of Neutralizing Antibodies to Incretin Molecules
Authors:
- Nichole A. ReynoldsNRNichole A. Reynolds
- Yan Q. ChenYCYan Q. Chen
- Richard E. HiggsRHRichard E. Higgs
- Boris CalderonBCBoris Calderon
- Jeff W. CramerJCJeff W. Cramer
- Nicoletta BiviNBNicoletta Bivi
- Michael E. HodsdonMHMichael E. Hodsdon
- Heather A. BullockHBHeather A. Bullock
- Travis E. ShockleyTSTravis E. Shockley
- Victoria L. PeekVPVictoria L. Peek
- Justin K. MackJMJustin K. Mack
- Deven LemenDLDeven Lemen
- 13 October 2025
- journal article
- Published by Springer Nature in The AAPS Journal
- Vol. 27 (6) , 160
Abstract
Formation of anti-drug antibodies (ADA) and, in particular, neutralizing antibodies (NAb), is a major risk to the development of biotherapeutics. Cell-based assays, which can reflect the mechanistic interactions among the drug, target, and NAb, are often most suitable for the detection of NAb. We report the development and validation of cell-based platform assays for a class of incretin molecules. An affinity capture elution step was employed to improve drug tolerance of a cell-based cyclic adenosine monophosphate (cAMP) assay. Assay conditions and procedures, including acid elution, cell density, and TAG labeled cAMP (cAMP-TAG) incubation time and concentration, were thoroughly optimized. Delta percent (Δ%) Neutralization was used to reduce assay variability during validation and sample analysis. This platform method has been applied to several incretin molecules and has demonstrated desired sensitivity, drug tolerance, and robustness.Keywords
This publication has 24 references indexed in Scilit:
- Transforming obesity: The advancement of multi-receptor drugsCell, 2024
- A competitive ligand binding assay for detection of neutralizing antibodies against an insulin analogJournal of Immunological Methods, 2023
- A sensitive and drug tolerant assay for detecting anti-AAV9 antibodies using affinity capture elutionJournal of Immunological Methods, 2022
- LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of conceptCell Metabolism, 2022
- LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of conceptMolecular Metabolism, 2018
- Affinity capture elution bridging assay: A novel immunoassay format for detection of anti-therapeutic protein antibodiesJournal of Immunological Methods, 2016
- Comparison of cell-based and non-cell-based assay platforms for the detection of clinically relevant anti-drug neutralizing antibodies for immunogenicity assessment of therapeutic proteinsJournal of Immunological Methods, 2015
- Immunogenicity of Biotherapy Used in Psoriasis: The Science Behind the ScenesJournal of Investigative Dermatology, 2015
- Comparison of competitive ligand-binding assay and bioassay formats for the measurement of neutralizing antibodies to protein therapeuticsJournal of Pharmaceutical and Biomedical Analysis, 2011
- An Affinity Capture Elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of high levels of drugJournal of Immunological Methods, 2007